Hyperglycemia and β-Cell Adaptation During Prolonged Somatostatin Infusion with Glucagon Replacement in Man

  1. Daniel Porte Jr
  1. Department of Medicine, University of Washington, the Division of Endocrinology and Metabolism, and Geriatric Research, Education, and Clinical Center, Veterans Administration Medical Center (151) 4435 Beacon Ave, S., Seattle, Washington 98108
  1. Address reprint requests to Dr. Ward at the above address.


To assess the relationship between β-cell function and the level and duration of hyperglycemia during generalized β-cell impairment, we studied the effects of acute and prolonged infusion of somatostatin in seven normal men. Twenty minutes after beginning an acute infusion of somatostatin (200 μg/h) plus glucagon replacement (0.75 ng/kg/min), plasma glucose (PG) remained unchanged, but plasma insulin (IRI) and acute insulin response to isoproterenol had fallen markedly. Seventy minutes after beginning somatostatin-plus-glucagon, a rise in PG was associated with an increase in the acute insulin response to isoproterenol, though not to the control level. In a separate study, after 46 h of the somatostatin-plus-glucagon infusion, at a glucose level similar to the 70-min level, plasma insulin had returned nearly to the control level and the acute insulin response to isoproterenol had returned completely to the control level. Such increases in basal and stimulated insulin secretion most likely represent a time-dependent adaptation by the β-cells to the persistent hyperglycemia. First- and second-phase insulin responses to intravenous glucose were markedly inhibited after 46 h of somatostatin-plus-glucagon. In summary, a 46-h infusion of somatostatin with glucagon replacement in humans leads to hyperglycemia, a slightly diminished basal insulin level, markedly decreased insulin responses to glucose, and an insulin response to isoproterenol maintained at a normal level by acute and probably chronic adaptation to the hyperglycemia. We speculate that β-cell adaptation to hyperglycemia may explain the similar abnormalities of islet function observed in patients with NIDDM.

  • Received October 12, 1982.
  • Revision received March 31, 1983.
| Table of Contents